Nura Bio Closes Series A Financing with $68 Million in New Funds, Bringing Total Raised to $140+ Million
2024年9月17日 - 7:30PM
ビジネスワイヤ(英語)
- Proceeds will support Nura Bio’s pipeline of
neuroprotective medicines
- Company announces successful completion of
Phase 1 study of NB-4746, Nura Bio’s brain-penetrant SARM1
inhibitor
- Shilpa Sambashivan, Ph.D., appointed CEO and
a Director of the company
Nura Bio Inc. (Nura Bio), a clinical-stage, biopharmaceutical
company developing neuroprotective, small molecule therapies for
the treatment of debilitating neurological diseases, announced
today the closing of more than $140 million in Series A financing.
This includes the addition of $68 million to the initial Series A
round of $73 million which was announced in 2020. The round was led
by founding investor The Column Group, with participation from
continuing investors Samsara Bio Capital and Euclidean Capital, and
new investor Sanofi Ventures.
This press release features multimedia. View
the full release here:
https://www.businesswire.com/news/home/20240917107266/en/
Shilpa Sambashivan, PhD, Chief Executive
Officer, Nura Bio (Photo: Business Wire)
The company also announced the appointment of Shilpa
Sambashivan, Ph.D., as Chief Executive Officer (CEO) and a company
Director. As a member of the founding team at Nura Bio and Chief
Scientific Officer (CSO), Dr. Sambashivan has been the driving
force behind Nura Bio’s bespoke research engine and differentiated
R&D pipeline, with the company’s first clinical candidate,
NB-4746, recently completing Phase 1 studies in healthy
volunteers.
“Under Shilpa’s leadership, Nura Bio has successfully
transitioned to a clinical-stage organization, making remarkable
progress in identifying ways to translate complex biology into
potential therapies,” said Tim Kutzkey, Ph.D., Managing Partner,
The Column Group and Nura Bio’s founding chairman. “We are excited
to continue to support the company through this next phase of
growth and clinical development. Shilpa’s leadership, combined with
her deep scientific expertise, will be key to maximizing Nura Bio’s
broad therapeutic potential in areas of large unmet need.”
Nura Bio’s financing close comes at a pivotal point with the
Phase 1 success of NB-4746, a brain-penetrant SARM1 inhibitor that
has been shown to prevent axon degeneration and provide
neuroprotection in multiple preclinical models of nerve injury and
disease. Nura Bio plans to initiate a Phase 1b/2 trial in a patient
population in 2025.
“At Nura Bio, we have been laser-focused on our mission of
delivering novel neuroprotective therapies to patients by
leveraging our deep scientific understanding of underlying disease
mechanisms including axon degeneration and neuroinflammation. The
strong support demonstrated by our investors through this financing
reflects the tremendous potential of our R&D pipeline,” said
Dr. Sambashivan. “I am proud of the results our team has delivered.
I look forward to leading the company through this next phase as we
prepare to test the SARM1 hypothesis in a patient population in
2025 with our lead candidate NB-4746 while continuing to advance
our promising preclinical pipeline.”
Results from the recently completed Phase 1 study of NB-4746 in
healthy volunteers show it was well-tolerated in the single
ascending and multiple ascending dose arms of the study. In this
Phase 1 study, NB-4746 achieved targeted plasma exposure levels
that the company believes are required for efficacy with no
associated serious treatment-emergent adverse events. Cerebrospinal
fluid levels of NB-4746 confirm brain penetration and support this
molecule's advancement in diseases that impact both the peripheral
and central nervous systems.
About NB-4746 NB-4746 is the lead asset in Nura Bio’s
small molecule pipeline. NB-4746 targets SARM1, a neuronally
enriched nicotinamide adenine dinucleotide (NAD) hydrolase that has
emerged as an important axon-intrinsic metabolic sensor and central
driver of axon degeneration. Axon degeneration is an early hallmark
of several neurological diseases. Halting axon degeneration early
can confer significant structural and functional neuroprotection
and has tremendous potential in the treatment of several
neurological diseases. Preclinical studies support the potential of
NB-4746 to provide broad axonal protection and functional
improvement across diseases of the central, peripheral, and ocular
nervous systems.
About Nura Bio Nura Bio, Inc. (Nura Bio) is a
clinical-stage biopharmaceutical company developing neuroprotective
therapies for the treatment of a broad range of neurological
diseases. Nura Bio’s research and early development small molecule
pipeline is focused on developing therapies that halt axon
degeneration and/or modulate microglial responses to degeneration
and injury, with the goal of conferring neuroprotection, across
diseases of the central, peripheral, and ocular nervous
systems.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20240917107266/en/
Lisa Guiterman Phone: +1 202-330-3431
lisa.guiterman@gmail.com